Ulcerative colitis is a chronic inflammatory bowel disease often associated with gastrointestinal symptoms and behavioral disorders such as anxiety. Given the established role of pro-inflammatory cytokines in gut–brain axis dysregulation, the present study aimed to evaluate the effects of dexpanthenol (DEX) on anxiety-like behaviors and inflammatory responses in a rat model of acetic acid (A.A)-induced colitis. Thirty-two rats were randomly assigned to four groups ( n = 8): control (saline), DEX 500 (dexpanthenol, 500 mg/kg, intraperitoneally), A.A (4% acetic acid, intracolonic), and A.A + DEX 500 (4% acetic acid plus dexpanthenol, 500 mg/kg, intraperitoneally). Anxiety-like behaviors were assessed using the open field, elevated plus maze, and light–dark box tests. Levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-1 beta (IL-1β) were measured in serum, colon, and hippocampal tissues. Rats with acetic acid-induced colitis exhibited significant anxiety-like behaviors, accompanied by increased IL-6, TNF-α, and IL-1β levels in the colon, serum, and hippocampus. Treatment with dexpanthenol attenuated anxiety-like behaviors and significantly reduced inflammatory cytokine levels in both peripheral and central tissues. The present study demonstrates that dexpanthenol improves anxiety-like behaviors in experimental colitis and is associated with reduced inflammatory responses in the colon, serum, and hippocampus. These findings indicate that colitis-associated behavioral alterations are accompanied by inflammatory changes, and warrant further mechanistic investigations to clarify the underlying mechanisms.
No takes yet. Share an insight, caveat, or question.
Rad et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: